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Abstract
An increasing number of patients with metastatic colorectal cancer (mCRC) are able to receive 3 or more lines of
therapy. Treatments in this setting can include regorafenib (an oral multikinase inhibitor), triﬂuridine/tipiracil hydro-
chloride (TAS-102), antibodies that target epidermal growth factor receptor for patients with RAS wild-type tumors (if
no prior exposure), and, where approved, anti-programmed cell death protein 1 inhibitors for patients with micro-
satellite instability-high mCRC. Although guidelines describe the available treatment options, few insights are provided
to guide selection and sequencing. In this article, we share expert opinion from diverse geographic regions, to offer
guidance for best practice when selecting and managing third-line treatment for mCRC. Various factors, including
performance status, age, and tumor sidedness, can be used to guide treatment selection. Biomarkers, such as RAS,
BRAF, and microsatellite instability, can be useful for treatment stratiﬁcation. Management of adverse events, to
maintain quality of life, is a key consideration and is crucial to best practice in this setting. Common toxicities
associated with third-line treatments are hand-foot skin reaction, fatigue, diarrhea, and cytopenias. Patients who
receive third-line and later-line treatments should be monitored for these events, especially during the ﬁrst 2 cycles.
Dose modiﬁcations can also be used to manage toxicities and to minimize the effect on quality of life, while maximizing
treatment beneﬁt. Clinical trials of emerging agents, new treatment combinations, and novel therapies continue the
efforts to improve outcomes for patients with mCRC. Sharing expert opinions on best practice for treatment selection
and management can ultimately improve outcomes for patients with mCRC.
Clinical Colorectal Cancer, Vol. 18, No. 1, e117-29 ª 2018 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Overall survival (OS) in patients with metastatic colorectal cancer
(mCRC) has been improving over the past 2 decades, and the
median has now reached more than 30 months.1-4 This increase has
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Best Practice in Third- or Later-line mCRCtype (WT) disease, an epidermal growth factor receptor (EGFR)
inhibitor.4-6
In the third-line and later-line setting, regorafenib and tri-
ﬂuridine/tipiracil are available for patients with mCRC4-6 whose
disease has progressed despite treatment with ﬂuoropyrimidine-,
oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular
endothelial growth factor (anti-VEGF) therapy and, if RAS WT,
an anti-EGFR therapy, or who have contraindications to these
treatments7,8 (Table 1 and Table 2). Regorafenib is an oral multi-
kinase inhibitor that was approved by the United States (US) Food
and Drug Administration (FDA) in 20127 and by the European
Medicines Agency (EMA) in 2013,24 and has since been made
available in several other countries worldwide, including Japan. The
combination of triﬂuridine and tipiracil hydrochloride (TAS-102) is
orally administered25 and was approved in Japan in 2014,26 in the
US in September 2015,8 and in Europe in 2016.27
The anti-programmed cell death protein 1 (anti-PD-1) immune
checkpoint inhibitors pembrolizumab and nivolumab were
approved in the US by the FDA in 2017, and nivolumab plus
ipilimumab was approved by the FDA in 2018,28 all in the second-
and later-line setting for patients with microsatellite instability-high
(MSI-H) or deﬁcient DNA mismatch repair mCRC whose disease
has progressed despite treatment with ﬂuoropyrimidine-, oxalipla-
tin-, and irinotecan-based chemotherapy (Table 3).29,31-33 At pre-
sent (October 2018), these agents are not approved for patients with
MSI-H mCRC in Europe and Japan.
Advances in the molecular proﬁling of tumors have resulted in
the identiﬁcation of new targets and combination therapies. Of
these, ERBB2 ampliﬁcation has emerged as a therapeutic target for
the 3.0% to 5.0% of patients who have CRC with this molecular
abnormality.34 Combination therapy using the anti-human
epidermal growth factor receptor 2 (HER2) antibody trastuzumab
plus the dual EGFR/HER2 kinase inhibitor lapatinib,35 or trastu-
zumab plus the HER2 dimerization inhibitor pertuzumab, has
shown promising clinical beneﬁt.36
As many patients are now receiving at least 3 lines of therapy,2 a
strategy for treatment in this setting, with goals including appro-
priate sequencing, is needed. Therefore, it is important to share
expert opinions on best practice for using the different treatment
options that are available. In this review, we share recommendations
and insights on selecting and managing treatment of mCRC in the
third-line or later-line setting from a panel of experts. The expert
panel that authored this review represents a variety of regions, and
their guidance reﬂects clinical and real-world evidence.
Selecting Treatment for mCRC in
the Third-line Setting
The European Society for Medical Oncology (ESMO) and Na-
tional Comprehensive Cancer Network (NCCN) guidelines both
outline the treatment options available for patients withmCRC in the
third-line setting and recommend treatments based on molecular
biomarkers. However, few insights are offered to guide the selection
and sequencing of treatments for this patient population.4,5 In the
absence of recommendations for treatment selection, sharing expert
opinions can provide guidance for best practice to optimize third-line
and later-line treatment of mCRC in the real world.- Clinical Colorectal Cancer March 2019Patient Characteristics
Patient characteristics, such as performance status (PS), age, and
comorbidities, as well as treatment goals and patients’ preferences,
are used to inform treatment selection for ﬁrst-line therapy4,5 and
thus can also be applied to subsequent lines of therapy. In later-
line settings, the number and class of previous therapies should
also be considered. In the third-line setting, patient selection is an
important indication of who will derive most beneﬁt from
systemic therapy, as there are currently no biomarkers that can
predict which patients will beneﬁt from regorafenib or triﬂuridine/
tipiracil.
This expert panel agreed that patients with a low burden of
disease or good PS typically tend to do well in the third-line and
later-line settings. However, the panel recommended that PS, age,
number and class of previous therapies, and patient’s preference all
be considered when deciding on a third-line treatment regimen.
Adverse events from prior systemic therapies should also be
considered, as such events can inﬂuence the choice of treatment.
For example, patients with baseline cytopenias are more likely to
receive regorafenib, whereas patients who experienced severe hand-
foot skin reaction or fatigue are more likely to receive triﬂuridine/
tipiracil. Comorbidities such as liver function should also be
considered, as patients with a PS of 0 or 1 who have good liver
function often derive long-term clinical beneﬁt from regorafenib
and triﬂuridine/tipiracil. Although patients with PS 2 at baseline
may not be good candidates for regorafenib or triﬂuridine/tipiracil,
patient age per se should not inﬂuence decisions on later-line
treatment regimens.
These expert opinions are based on evidence from several clinical
studies of regorafenib and triﬂuridine/tipiracil. In the CONSIGN
(open-label phase 3b study of regorafenib in patients with mCRC;
NCT01538680) study, patients treated with regorafenib who
experienced a long progression-free survival (PFS) were more likely
to have a more favorable baseline PS than those who had a short
PFS.37 Of those patients who achieved a PFS of > 4 months, 58%
were PS 0 at baseline and 41% were PS 1, whereas of those with
PFS of < 4 months, 44% were PS 0 at baseline and 56% were PS 1.
A similar relationship was also observed in a real-world study
(RECORA [regorafenib in patients with mCRC after failure of
standard therapy; NCT01959269]), in which OS and PFS were
shorter in patients with PS 2 than those with PS 0 or 1.15 Median
PFS was 3.6 months (95% conﬁdence interval [CI], 3.1-5.0
months) in patients who were PS 0 at baseline compared with 2.5
months (95% CI, 1.9-2.9 months) in patients who were PS 2 (P ¼
.002). Poor PS unfavorably affected survival in a study nested in a
compassionate-use program (REBECCA [REgorafeniB in mEta-
static Colorectal cancer in a French Compassionate Use progrAm;
NCT02310477]).14 PS did not seem to signiﬁcantly inﬂuence the
efﬁcacy of triﬂuridine/tipiracil in the RECOURSE (retrospective
cohort study of TAS-102 in patients with mCRC; NCT01607957)
trial,21,38 and triﬂuridine/tipiracil has shown efﬁcacy in a clinical
trial that included patients with a PS of 2.39 Clinical trial results
have also shown that mild-to-moderate hepatic or renal impairment
does not affect the exposure of regorafenib.7 Furthermore, although
the prescribing information for triﬂuridine/tipiracil recommends
considering the presence of comorbidities when selecting this
Table 1 Patient Outcomes in Clinical Trials and Real-world Studies of Regorafenib
Study Study Location
No. Regorafenib-
treated Patients
Median OS,
mos (95% CI)
Median PFS,
mos (95% CI)
Median Treatment
Duration, mos
Patients With ‡ 1
Drug-related
AE, n (%)
Patients With ‡ 1
Grade ‡ 3
Drug-related
AE, n (%)
CORRECT9,10 Global 505 6.4 (NA) 1.9 (NA) 2.8 465 (93) 270 (54)
CONCUR11 Asia 136 8.8 (7.3-9.8) 3.2 (2.0-3.7) 2.4 132 (97) 74 (54)
CONSIGN12 Global 2864 NA 2.7 (2.6-2.7) 2.5 NA NA (57)
CORRELATE13 Global 500a NA NA 2.4 NA (76) NA (31)
REBECCA14 France 654 5.6 2.7 2.2 524 (80) 288 (44)b
RECORA15 Germany 458 5.6 (5.2-6.6) 3.2 (2.9-3.5) NA 288 (63) 77 (17)
Kopeckova et al, 201716 Czech Republic 148 9.3 (5.6-13.0) 3.5 (2.7-4.2) 2.9 NA 5 (3)c
Calcagno et al, 201617 France 29 6 (5-8) NA 2.5 25 (86) NA
Xu et al, 201818 Korea 32 NR 4.2 (3.1-5.2) NA NA 12 (38)
Japan PMS19 Japan 787 7.0 (6.3-7.8) NA NA 702 (89) NA
REGOTAS20 Japan 223 7.9 (6.8-9.2) 2.1 (2.0-2.4) NA NA Hematologic: 30 (13)
Nonhematologic: 104 (47)
Abbreviations: AE ¼ adverse event; CI ¼ conﬁdence interval; NA ¼ not available; NR ¼ not reached; OS ¼ overall survival; PFS ¼ progression-free survival; PMS ¼ post-marketing surveillance.
aInterim analysis.
bOf 512 patients among whom data on worst grade was available.
cAny AEs (not speciﬁcally drug-related).
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Table 2 Patient Outcomes in Clinical Trials and Real-world Studies of Triﬂuridine/tipiracil
Study Location
No. Triﬂuridine/
Tipiracil-treated
Patients
Median OS,
mos (95% CI)
Median PFS,
mos (95% CI)
Patients With ‡ 1
Drug-related
AE, n (%)
Patients With ‡ 1
Drug-related
Grade ‡ 3
AE, n (%)
RECOURSE21 Multinational 534 7.1 (6.5-7.8) 2.0 (1.9-2.1) 524 (98) 370 (69)
TERRA18 Asia 406 7.8 (NA) 2.0 (NA) NA NA
Compassionate use
Program22
Global 879 NA NA NA NA
Japan PMS study23 Japan 3420 NA NA 219 (6)a NA
REGOTAS20 Japan 327 7.4 (6.6-8.3) 2.1 (2.0-2.3) NA Hematologic: 128 (39)
Nonhematologic: 41 (13)
Abbreviations: AE ¼ adverse event; CI ¼ conﬁdence interval; NA ¼ not available; OS ¼ overall survival; PFS ¼ progression-free survival; PMS ¼ post-marketing surveillance.
aSpontaneous reports of triﬂuridine/tipiracil adverse drug reactions by attending physicians.
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e120treatment,8 real-world ﬁndings suggest that mild-to-moderate he-
patic or renal impairment does not seem to affect survival.40 Finally,
clinical data suggest that patient age does not affect the clinical
beneﬁt from either regorafenib or triﬂuridine/tipiracil.38,41,42 In the
CONSIGN trial of regorafenib, 78% of patients were < 70 years of
age and 22% were  70 years of age. A subgroup analysis by age
showed that median PFS was similar across the age groups. In
patients < 70 years of age, the median PFS was 2.7 months (95%
CI, 2.6-2.8 months) and 2.5 months (95% CI, 2.3-2.7 months) in
those  70 years of age.41 The dose received, duration of treatment,
and rates of treatment modiﬁcations, as well as the safety proﬁle,
were also generally comparable between age groups.
The expert panel agreed that patients who have not previously
received bevacizumab may derive greater beneﬁt from regorafenib
than those who have received prior bevacizumab therapy. This is
supported by clinical study results that have shown that the beneﬁt
of treatment with regorafenib and triﬂuridine/tipiracil may increase
with fewer prior therapies.9,11,43 The REVERCE (randomised phase
2 study of regorafenib followed by cetuximab versus the reverse
sequence in patients with mCRC; UMIN000011294) study
compared the efﬁcacy and safety of regorafenib followed by cetux-
imab versus cetuximab followed by regorafenib. The results from
this study showed that patients who received regorafenib followed
by cetuximab experienced longer PFS with second treatment (PFS2;
5.2 vs. 1.8 months; hazard ratio [HR], 0.29) and OS (17.4 vs. 11.6
months; HR, 0.61; P ¼ .03) than those who received cetuximab
prior to regorafenib.44
Currently, it is unclear how PS, age, and comorbidities may affect
the response to nivolumab, nivolumab plus ipilimumab orTable 3 Outcomes with Nivolumab and Pembrolizumab in Patients
Location
Number of
Patients
ORR, %
(95% CI)
Nivolumab29 Global 74 31.1 (20.8-42.
Nivolumabþ
ipilimumab30
Global 119 55 (45.2-63.
Pembrolizumab31 Global 61 26.2 (15.8-39.
Abbreviations: AE ¼ adverse event; DCR ¼ disease control rate ( 12 weeks); ORR ¼ overall res
- Clinical Colorectal Cancer March 2019pembrolizumab in patients with MSI-H CRC. Although sub-
analyses may provide some indication, the clinical trials did not
enroll patients with a PS of 2, and few patients  65 years of age
were included.29,31 Therefore, it would be of interest to understand
the response to nivolumab, nivolumab plus ipilimumab or pem-
brolizumab in older patients with MSI-H CRC and those
with PS 2.
Molecular Biomarkers
Several biomarkers are used to inform treatment selection and
understand the prognosis for patients with mCRC; the most
common are RAS (KRAS and NRAS exons 2, 3, and 4), BRAF, and
MSI; HER2 is an emerging target.34,45 None of these molecular
markers have been associated with response to regorafenib or tri-
ﬂuridine/tipiracil.46-48
This expert panel recommended that biomarkers are tested at
diagnosis and should include RAS, BRAF, and MSI. Although some
experts also recommend testing for HER2 at diagnosis, the expert
from France feels the evidence is not clear for HER2 testing at
diagnosis. The presence of RASmutations excludes the use of EGFR
inhibitors, such as cetuximab and panitumumab, as patients with
such mutations do not derive beneﬁt from these agents and they
may have a detrimental effect. The expert panel also agreed
that a BRAF V600E mutation suggests using FOLFOXIRI
(5-ﬂourouracil, leucovorin, oxaliplatin, and irinotecan)/bev-
acizumab as ﬁrst-line treatment, followed by a clinical trial, or an
EGFR inhibitor in combination with a MEK inhibitor and a BRAF
inhibitor, if available. HER2 positivity suggests delaying the use of
an EGFR inhibitor and enrolling the patient in a clinical trial or, ifWith MSI-H mCRC
DCR, %
(95% CI)
Patients With ‡ 1
Drug-related
AE, %
Patients With ‡ 1
Drug-related
Grade ‡ 3
AE, %
9) 69 (57-79) 49 20
8) 80 32
1) 50.8 (37.7-63.9) Not speciﬁed Not speciﬁed
ponse rate.
Tanios Bekaii-Saab et alavailable off-trial, initiating dual HER2 blockade. MSI-H positivity
suggests that the approved PD-1 inhibitors (nivolumab and pem-
brolizumab)32,33 should be used in the second-line or later-line
settings in the US,49 although these immunotherapies remain
investigational in Europe, so MSI status testing is used to assist in
genetic counseling.4
Studies investigating novel biomarkers, such as carbohydrate
antigen-19, CCL5/CCR5 pathway genes, and DNA repair-related
genes, for regorafenib and triﬂuridine/tipiracil are ongoing.50-53 A
biomarker for these treatments would be valuable for informing
patient selection and may improve patient quality of life by avoiding
exposure to unnecessary toxicities. Molecular classiﬁcation of indi-
vidual CRC tumors through the consensus molecular subtypes54
remains investigational, and the effect on clinical practice is unclear.
Tumor Sidedness
Tumor sidedness is an important prognostic factor in mCRC, as
tumors that originate on the right are associated with poorer out-
comes than those originating on the left side.43 Furthermore,
sidedness may also be predictive of response to treatment in the
ﬁrst-line setting; greater beneﬁt from treatment with an anti-EGFR
therapy was observed in patients with RAS WT disease who had
left-sided tumors than in patients with right-sided tumors.43 Indeed,
bevacizumab plus chemotherapy may provide greater clinical beneﬁt
than anti-EGFR therapies in patients with right-sided tumors.55
This expert panel agreed that tumor sidedness does not seem to
affect response to regorafenib or triﬂuridine/tipiracil in the third-line
setting. Some members of the panel advised that they do not usually
use anti-EGFR therapies in patients with right-sided tumors,
including those with RASWT disease, but do use these treatments in
patients with left-sided tumors. These experts expressed a preference
for bevacizumab for the treatment of patients with right-sided tumors
in the ﬁrst-line setting. Other panel members suggested that triplet
chemotherapy plus an EGFR inhibitor or plus bevacizumab are also
treatment options for left-sided and right-sided tumors, respectively.
A sub-analysis of the CORRELATE (prospective observational trial
of regorafenib in mCRC; NCT01843400) study showed that tumor
sidedness did not affect response to regorafenib, as OS was similar for
right-sided and left-sided tumors; 6.3 and 6.7 months, respectively
(P ¼ .278).13 Similarly, an analysis of both regorafenib and tri-
ﬂuridine/tipiracil found that time to treatment failure and OS were
unaffected by tumor location.56
Although nivolumab, nivolumab plus ipilimumab and pem-
brolizumab are available in later-line settings for patients with MSI-
H mCRC, the effect of tumor sidedness on response to these
treatments has not yet been assessed. MSI has been associated with
right-sidedness and a poor response to EGFR-targeted therapies,5,57
but further evidence is needed before this association can be
translated into clinical practice.
Managing Third-line Treatment for
mCRC
Prevention and Management of Adverse Events (AEs)
Maintaining quality of life is an essential goal for third-line and
later-line treatments for patients with mCRC. The prevention and
management of AEs are key factors in achieving this goal and so are
crucial to best practice for management of this patient population.The most common regorafenib-related AEs observed in clinical
studies were hand-foot skin reaction, fatigue, diarrhea, and hyper-
tension.12 These AEs tend to emerge early and attenuate over time,
even when dosage is maintained.10-12 The most common
triﬂuridine/tipiracil-related AEs in clinical trials were hematologic,
nausea/vomiting, diarrhea, decreased appetite, and fatigue.21 Im-
mune checkpoint inhibitor therapies, such as pembrolizumab and
nivolumab, are associated with immune-mediated reactions and
infusion-related reactions.32,33 It is unclear whether there are any
nuances in the AE proﬁles of pembrolizumab and nivolumab in
patients with MSI-H mCRC compared with other tumor types. A
recent study of cobimetinib plus atezolizumab, atezolizumab alone,
and regorafenib in patients with microsatellite stable CRC, which
did not meet the primary endpoint, showed that treatment-related
AEs of any grade with > 30% occurrence were diarrhea (56%),
rash (42%), and nausea (32%) with combination therapy and none
with atezolizumab monotherapy.58
This expert panel agreed that early onset of hand-foot skin re-
action (Figure 1) in response to regorafenib treatment may be
associated with duration of OS. However, hand-foot skin reaction is
one of the most common reasons for treatment discontinuation, so
careful management is important. The expert panel agreed that
healthcare professionals need to be well-informed about the risks
for, and management of, hand-foot skin reaction during long-term
treatment with regorafenib. In the CORRECT (patients with
mCRC treated with regorafenib or placebo after failure of standard
therapy; NCT01103323) study, hand-foot skin reactions of any
grade occurred in 47% of patients who received regorafenib,
compared with 8% of those who received placebo, and of these 17%
and < 1%, respectively, were grade 3.9 Hand-foot skin reactions
associated with regorafenib typically manifest within 4 weeks of
treatment initiation9,10 and can negatively affect patient quality of
life.59 These reactions seem to be more common in Japanese pa-
tients (80%) than in non-Japanese patients (42%).60 Guidance on
the management of hand-foot skin reaction recommends main-
taining skin moisture and integrity using emollients and creams.
Urea (10%-40%) and salicylic acid (5%-10%) creams are also
recommended, as keratolytics and topical analgesic gels can be used
to relieve pain. Antiseptic baths, topical corticosteroids, antibiotics,
and systemic pain relief can be added to the management regimen
for higher grades of hand-foot skin reaction.61
Fatigue is a common symptom in advanced cancer, particularly in
the third-line and later-line settings, as observed in the placebo arm
of the CORRECT study,9 and is often multifactorial. Fatigue can
have a signiﬁcant effect on quality of life, and there is no approved
pharmacologic treatment to offer patients. Although clinical evi-
dence suggests that medical prophylactic treatment with low-dose
corticosteroids, such as dexamethasone 2 mg/day,62 may reduce
regorafenib-related fatigue, this expert panel also agreed that non-
pharmacologic interventions, general supportive care, regular
physical activity, and psycho-educational support, as well as rest and
exercise,63,64 may be beneﬁcial for managing fatigue.
Fatigue of any grade occurred in 47% of patients who received
regorafenib in the CORRECT study, compared with 28% of those
who received placebo, with grade  3 events occurring in 10% and
5% of patients, respectively.9 Hypothyroidism has been related to
fatigue in patients receiving regorafenib and was easily reversed byClinical Colorectal Cancer March 2019 - e121
Figure 1 Images of Hand-Foot Skin Reactions (HSFRs). A, Grade 1 HFSR. Erythema and Mild Desquamation; B, Grade 2 HFSR. Painful
Erythema, Desquamation, and Hyperkeratosis at Pressure Points; C, Grade 3 HFSR
Photos provided by Marcela Moreno and Juan M O’Connor, Dermatooncology, Instituto Fleming, Argentina.
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Table 4 Expert Opinion on Monitoring Patients Receiving Third-line Therapies
Therapy Events to Monitor Monitoring Frequency
Regorafenib Hand-foot skin reaction Cycles 1 and 2: weekly or biweekly
Skin rash Subsequent cycles: monthly
Fatigue
Diarrhea
Liver function
Blood pressure
Triﬂuridine/tipiracil Hematologic events (especially in patients with previous events) Cycles 1 and 2: weekly or biweekly
Subsequent cycles: monthly
Tanios Bekaii-Saab et alL-T4 administration,65 suggesting that routine assessment of
thyroid function in patients with fatigue may be beneﬁcial. How-
ever, additional evidence is needed before this is adopted as standard
practice.
Diarrhea is associated with regorafenib treatment, and a long-
lasting low-grade event can affect a patient’s quality of life more
than a grade 3 event of short duration. Diarrhea was common
among patients receiving regorafenib in the CORRECT and GRID
(Gastrointestinal stromal tumors - Regorafenib In progressive Dis-
ease; NCT01271712) studies.7,9,66 In the CORRECT study,
diarrhea of any grade occurred in 34% of patients who received
regorafenib and 8% who received placebo, and of these, 7% and
1%, respectively, were grade 3.9 This expert panel recommended
patient education on the need to report and manage diarrhea. Pa-
tients who experience severe diarrhea may beneﬁt from octreotide
acetate, which provides rapid control and prevents severe dehydra-
tion.67,68 Oral mucositis (stomatitis) has also been associated with
regorafenib treatment, and the intensity may be inﬂuenced by pa-
tient age, dental hygiene, nutritional status, and associated in-
fections. In the CORRECT and GRID studies of regorafenib, oral
mucositis (stomatitis) was observed, usually at the end of the ﬁrst
week of treatment.9,66 In the CORRECT study, oral mucositis of
any grade occurred in 27% of patients who received regorafenib and
4% of patients who received placebo, with grade 3 events occurring
in 3% and 0% of patients, respectively.9 Preventative measures,
such as good oral hygiene and dental care, for reducing the risk of
this event are also recommended. Liver abnormalities can occur
with regorafenib treatment and can be severe. Liver abnormalities
were observed with regorafenib in the CORRECT study, including
1 case of fatal liver dysfunction.9,66 As these abnormalities usually
emerge soon after treatment initiation, this expert panel suggested
carrying out liver function tests every 2 weeks during the ﬁrst 2
cycles, and modifying treatment as needed, based on clinical prac-
tice guidelines.
The recent ReDOS (REgorafenib Dose Optimization Study;
NCT02368886) study assessed a dose-escalation strategy that star-
ted regorafenib at 80 mg and escalated weekly (as toxicity allowed)
to 160 mg, in comparison with the approved 160 mg starting dose.
The dose-escalation strategy was found to be associated with lower
rates of grade 3/4 toxicities, including hand-foot skin reaction, fa-
tigue, and hypertension, than the approved 160 mg starting dose.69
This allows the dosing of regorafenib to be optimized for individual
patients.Triﬂuridine/tipiracil is also associated with diarrhea. In the
RECOURSE study, diarrhea of any grade was observed in 32% of
patients who received triﬂuridine/tipiracil, compared with 12% who
received placebo.21 Triﬂuridine/tipiracil is also associated with
nausea and vomiting; in the RECOURSE study, 48% of patients
experienced nausea of any grade and 28% experienced vomiting of
any grade, compared with 24% and 14%, respectively, in the pla-
cebo group.21 As these events occur frequently, are common to
many therapies, and can inﬂuence adherence,70 it is important that
they are managed effectively.
Results from the RECOURSE trial have also shown that treat-
ment with triﬂuridine/tipiracil was associated with anemia (77%),
leukopenia (77%), neutropenia (67%), and thrombocytopenia
(42%) of any grade.21 As these events occur frequently and can be
serious, complete blood counts should be taken prior to initiating
therapy and on day 15 of every cycle.8 Triﬂuridine/tipiracil should
only be initiated in patients with absolute neutrophil counts
(ANCs) of  1500/mm3, any incidence of febrile neutropenia has
resolved, platelet counts of  75,000/mm3 and any grade 3/4
nonhematologic AEs have resolved to grade 0 or 1. Furthermore,
triﬂuridine/tipiracil should be withheld if ANCs are < 500/mm3 or
febrile neutropenia occurs, platelet counts are < 50,000/mm3 and
there are any grade 3/4 non-hematological AEs. Treatment with
granulocyte-colony stimulating factor (G-CSF) has been shown to
reduce the incidence of febrile neutropenia in the RECOURSE
study, in which more patients who received triﬂuridine/tipiracil
were treated with G-CSF than those who received placebo.71
Immune-mediated reactions are not uncommon in patients
receiving treatment with immune checkpoint inhibitor therapies,
although rates of life-threatening or fatal events are low.29,31-33
Prompt recognition and management of immune-mediated events
are crucial, and optimal management is dependent on the organ
involved and the severity. Guidelines for identifying and managing
immune-mediated events are currently available from ESMO,72
American Society of Clinical Oncology (ASCO),73 and NCCN,74
and provide practical information, so their use is strongly advised.
In most cases, immunotherapy should be suspended or dis-
continued (depending on the severity and organ system involved) in
patients experiencing an AE of moderate (grade 2) or greater
severity. This expert panel agreed that corticosteroids are the
mainstay of treatment for patients experiencing severe or life-
threatening toxicities; however, in cases of severe and steroid-
refractory toxicity, inﬂiximab or other immunosuppressiveClinical Colorectal Cancer March 2019 - e123
Table 5 Expert Opinion on Dose Modiﬁcation in the Third-Line Setting
Therapy Approach
Regorafenib Patients with poor PS: start at 80 mg or 120 mg and gradually increase or modify in response to beneﬁt and tolerability
Dosing should be suspended for any severe or life-threatening AEs (grade  3), symptomatic (grade  2) hypertension, or moderate
(grade 2) hand-foot skin reaction that does not resolve within 1 week of dose reduction
Treatment can be reintroduced at 80 mg or 120 mg once symptoms have resolved and the risk of event recurrence is mitigated
Treatment should be discontinued if 80 mg is intolerable, or in cases of severe or life-threatening hepatotoxicity
Triﬂuridine/tipiracil If hematologic AEs occur, a new cycle of treatment should not be started until the ANC  1500, platelets  75,000, and all severe
(grade  3) nonhematologic AEs have resolved
After recovery, treatment can be reintroduced at a dose 5 mg/m2 lower in cases of febrile neutropenia, uncomplicated grade
4 neutropenia or thrombocytopenia resulting in more than 1-week delay in starting the next cycle, and severe (grade 3) nonhematologic
side effects that cannot be adequately managed with supportive care
Abbreviations: AE ¼ adverse event; ANC ¼ absolute neutrophil count; PS ¼ performance status.
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e124therapies may be beneﬁcial. Endocrinopathies can be managed with
hormone replacement and may not require treatment discontinua-
tion or steroids. Management of immune-mediated events by an
experienced multi-disciplinary team can help mitigate and prevent
the most serious complications associated with immune therapies,
helping to maintain patient quality of life.
Patient Monitoring
The toxicities associated with third-line and later-line therapies
mean patient monitoring is needed7,8,24,27 to minimize the impact
of these on patient quality of life, as well as maximizing the beneﬁt
of treatment.
This expert panel agreed that patients should be monitored
closely during treatment with regorafenib, for hand-foot skin reac-
tion, skin rash, diarrhea, fatigue, and changes in liver function and
blood pressure. Monitoring should be carried out weekly or
biweekly during the ﬁrst 2 cycles of treatment when these AEs occur
most commonly, and monthly thereafter. Close monitoring is also
recommended for patients receiving triﬂuridine/tipiracil and is
particularly important for those who have experienced previous
neutropenia, anemia, or thrombocytopenia (Table 4). These expert
opinions are based on the prescribing information, clinical study
data, and clinical practice guidelines, which state that regorafenib
monitoring should be carried out weekly during the ﬁrst 2 cycles of
treatment and monthly thereafter,75 with special attention to tox-
icities detected during prior cycles to prevent their wors-
ening.63,75,76 Similarly, triﬂuridine/tipiracil monitoring should be
weekly or biweekly following treatment initiation.8,27 Expert
opinions from Korea and France describe a slightly different
approach to patient monitoring in their clinics, with weekly follow-
up only during the ﬁrst cycle of treatment.
This panel agreed that monitoring of patients who are receiving
nivolumab or pembrolizumab should closely follow the guidelines,
with patients being monitored at each infusion and with increased
frequency in cases of suspected toxicity.
Dose Modiﬁcation
The licensed starting dose of regorafenib is 160 mg once-daily on
a 3-weeks on/1-week off schedule.7 The recommended starting dose- Clinical Colorectal Cancer March 2019of triﬂuridine/tipiracil is 35 mg/m2 up to a maximum of 80 mg per
dose (based on the triﬂuridine component) taken orally twice daily
on day 1 to 5 and day 8 to 12 of each 28-day cycle.8,27 The rec-
ommended starting dose for nivolumab is 240 mg every 2 weeks
and for pembrolizumab is 200 mg every 3 weeks.32,33 However, to
maintain patient quality of life and maximize treatment beneﬁt,
dose modiﬁcations may be needed to address toxicities, such as
hand-foot skin reaction, gastrointestinal AEs, fatigue, cytopenias,
and immune-mediated reactions.7,8,24,27,32,33
The expert panel agreed that some prescribers are using alterna-
tives to the standard regorafenib dosing schedule in some patients,
such as those with poor PS scores. The regorafenib dose is gradually
increased from a starting dose of 80 mg or 120 mg, depending on
the clinical beneﬁt and tolerability in each patient (Table 5), similar
to the approach used in the ReDOS study.69 However, the panel
highlighted that alternatives to the 160 mg once daily on a 3-weeks
on/1-week off schedule are not approved. The panel recommended
that dose modiﬁcations of regorafenib and triﬂuridine/tipiracil are
carried out based on the prescribing information (Table 5).7,8,24,27
Regorafenib should be suspended if a patient experiences any
severe or life-threatening AEs (grade  3), symptomatic (grade  2)
hypertension, or moderate (grade 2) hand-foot skin reaction that
does not resolve within 1 week of dose reduction. Once symptoms
have resolved and the risk of the event recurring has been mitigated,
reintroducing regorafenib at a lower dose, such as 80 mg or 120 mg,
should be considered. If hepatotoxicity occurs, treatment, even at a
reduced dose, should be resumed with caution. Regorafenib should
be discontinued if the patient is unable to tolerate the 80 mg dose,
or in cases of severe or life-threatening hepatotoxicity. Clinical data
have also shown that dose modiﬁcations or temporary discontinu-
ation of therapy do not seem to negatively affect the efﬁcacy of
regorafenib.9,11,14,77,78
Results from the ReDOS study have shown that a signiﬁcantly
larger proportion of patients start a third cycle of regorafenib when
the dose is escalated weekly from 80 mg to 120 mg and then to 160
mg over the cycle, compared with starting at 160 mg (43% vs. 25%;
P ¼ .028; including patients with disease progression before starting
the third cycle).69 In the Japanese phase II dose titration study
(UMIN000018968), in which the starting dose of regorafenib was
Figure 2 Proposed Treatment Sequencing Strategy in Third-line and Later-lines for Patients With Metastatic Colorectal Cancer
Abbreviations: HER2 ¼ Human Epidermal Growth Factor Receptor 2; MSI-H ¼ microsatellite instability-high; PS ¼ performance status; SIRT ¼ selective internal radiation therapy. Anti-EGFR
therapies can be used in this setting, if not used previously (and as indicated). (?) Indicates this is a suggested approach.
Tanios Bekaii-Saab et al120 mg, the disease control rate (36.7%) was comparable with re-
sults from the CORRECT trial (41%).9,79 In addition to ReDOS,
several ongoing clinical trials are currently investigating dose-
escalation protocols for regorafenib, including REARRANGE
(study comparing different dose approaches of induction treatment
of regorafenib in mCRC; NCT02835924), the results from which
are expected in 2019, and will be important for informing the
optimal starting dose of regorafenib in clinical practice.
If hematologic AEs occur during treatment with triﬂuridine/
tipiracil, a new cycle of treatment should not be started until the
ANC  1500, platelets  75,000, and all severe (grade  3)
nonhematologic AEs have resolved. Complete blood cell counts are
advised on day 1 and day 15 of each cycle. Triﬂuridine/tipiracil
should be suspended if ANC < 500, febrile neutropenia occurs,
platelets < 50,000, and for all severe (grade  3) nonhematologic
AEs. After recovery, reintroducing triﬂuridine/tipiracil at a dose that
is 5 mg/m2 lower is recommended in cases of febrile neutropenia,
uncomplicated grade 4 neutropenia, or thrombocytopenia resulting
in more than a 1-week delay in starting the next cycle, and severe
(grade  3) nonhematologic AEs that cannot be adequately
managed with supportive care, as described in the prescribing in-
formation.8 In addition, G-CSF can be used as proactive supportive
care in patients treated with triﬂuridine/tipiracil who experience
neutropenia.23
This expert panel also recommended that treatment with
nivolumab and pembrolizumab is suspended or permanently dis-
continued in patients who experience moderate, severe, or life-
threatening toxicity, depending on the organ system involved and
severity of the complications.Clinical Markers of Response
The expert panel agreed that some class-effect events, such as
arterial hypertension with regorafenib and myelosuppression with
triﬂuridine/tipiracil, have been observed, but neither of these events
seemed to indicate any clinical beneﬁt. In addition, the expert panel
agreed that the occurrence of hand-foot skin reaction and lung nodule
cavitation may be predictors of long-term response to regorafenib.
Changes such as density reduction in lungmetastases, lungmetastases
cavitation, and longer time from ﬁrst diagnosis to metastatic disease
have been associatedwith favorable responses to regorafenib in clinical
studies.37,80,81 Such events may encourage clinicians and patients to
persist with therapy, using dose adjustments to manage toxicities
when necessary.14,19,23,82-87 However, more evidence is required to
determine whether such clinical responses could be used as robust
markers that inform clinical decisions.
Several ongoing trials are investigating the use of imaging for the
early identiﬁcation of response to regorafenib (Kehagias et al, 201888;
NCT02175095 and JACCRO CC-12 [phase 2 study to evaluate the
efﬁcacy of regorafenib in mCRC patients by FDG-PET/CT;
UMIN000015563]; TEXCAN [evaluation of treatment response
with CHOI and RECIST criteria and CT texture analysis in patients
with mCRC treated with regorafenib; NCT02699073]; KSCC1603
[retrospective cohort study for assessment of imaging changes after the
use of regorafenib; UMIN000023329]), which would provide valu-
able additional evidence for conﬁrming treatment response.
Treatment Sequencing
Appropriate treatment sequencing enables patients to receive all
available agents, which is a key therapeutic goal in later-line settings.Clinical Colorectal Cancer March 2019 - e125
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line or later-line therapy for patients with mCRC, where available
and as indicated, along with nivolumab and pembrolizumab in
eligible patient populations. However, treatment sequencing de-
cisions can be challenging, and although NCCN guidelines
recommend using nivolumab or pembrolizumab before regorafenib
or triﬂuridine/tipiracil for patients with MSI-H mCRC, there is
little other evidence to guide the sequencing of the different options.
NCCN guidelines recommend sequential treatment with regor-
afenib and triﬂuridine/tipiracil, with the order of treatment at the
discretion of the clinician; ESMO guidelines do not make any clear
recommendations.4-6
Although there are no sequencing data from phase III studies, the
expert panel agreed that regorafenib may provide more beneﬁt when
used earlier in the treatment paradigm. Furthermore, triﬂuridine/
tipiracil is often well-tolerated, so may be more suitable as a later-
line therapy and is equally effective whether patients have received
regorafenib previously. The algorithm proposed in Figure 2 sum-
marizes these expert opinions. In the RECOURSE study, the OS
hazard ratio for patients who had received regorafenib prior to tri-
ﬂuridine/tipiracil and those who had not was 0.69 for both groups.
There was no signiﬁcant difference in OS between patients treated
with triﬂuridine/tipiracil who had or had not previously received
regorafenib.21 Results from a further study in Japan showed that the
median PFS in those who received regorafenib prior to triﬂuridine/
tipiracil was 4.6 months, compared with 1.9 months in those who
did not.89 In addition, as described above in the REVERCE study,
survival was longer for patients who received regorafenib followed
by cetuximab than those who received cetuximab prior to
regorafenib.44
Immunotherapies provide beneﬁt but are limited to the small
proportion (< 5%) of patients with MSI-H disease, in whom they
are highly effective. Therefore, patients with MSI-H disease should
be referred as expeditiously as possible to receive immune check-
point inhibitors (Figure 2). Similarly, if patients have tumors with
an ERBB2 ampliﬁcation (< 5% of cases) HER2-targeted combi-
nation therapy can be considered. There is only a low level of evi-
dence for chemotherapy re-challenge, although further data are
expected (Figure 2).
The expert panel recognized that many US clinicians use regor-
afenib following chemotherapy reintroduction; however, there is
little evidence to support this strategy.2 Indeed, no randomized
study has addressed this question to date. Furthermore, the response
to chemotherapy reintroduction can vary widely based on previous
response to chemotherapy and the time since the prior treatment.90
Results from clinical studies suggest that re-challenge with oxali-
platin may be suitable when no other treatment options are avail-
able, but it should be used with caution, as it can lead to additional
toxicity18,91,92 and is often not feasible because of residual periph-
eral neuropathy.93 Some data are available that suggest that regor-
afenib may have a chemosensitizing effect, allowing re-challenge
with chemotherapy after disease progression92,94; however, addi-
tional investigations into this effect are needed before expert guid-
ance can be offered.
The plasticity of CRC cells and the dynamic clonal competition
that takes place during EGFR-targeted therapy and on withdrawal
of EGFR blockade might also be exploited in the clinic, as the- Clinical Colorectal Cancer March 2019decline of mutated RAS clones may renew the response to EGFR
antibodies.92,95,96 This observation provides a molecular rationale
for studies that proposed re-challenge with cetuximab97,98 or pan-
itumumab99,100 in patients with RAS WT disease after a previous
response to anti-EGFR therapy. Additional studies investigating
different re-challenge strategies using anti-EGFR therapies are
ongoing and needed before integrating this approach into standard
clinical practice.92
At present, the evidence suggesting the use of regorafenib earlier
and triﬂuridine/tipiracil later in the treatment cycle is anecdotal.
More data are required to determine the optimal sequencing of
regorafenib and triﬂuridine/tipiracil as third-line or later-line ther-
apy for mCRC, which will enable expert guidance to be provided
and will assist with maximizing the beneﬁt for patients.Discussion
Current options for third-line and later-line treatment of patients
with mCRC include regorafenib and triﬂuridine/tipiracil, and in
patients with MSI-H mCRC, nivolumab, nivolumab plus ipili-
mumab, and pembrolizumab, where available. The expert opinions
on best practice for treating patients with mCRC described here
complement clinical guidelines and include consideration of patient
characteristics, molecular biomarkers, and appropriate treatment
sequencing, as well as effective management of AEs and dosing to
optimize overall outcomes and improve quality of life. Best practice
for treating patients with mCRC will continue to evolve as clinical
trials of emerging agents, new treatment combinations, and novel
therapies continue the efforts to improve outcomes for patients with
mCRC.
Further clinical studies investigating the current treatment op-
tions are underway, as we continue to improve our understanding of
the use of these therapies in the real world. In particular, nivolumab,
nivolumab plus ipilimumab and pembrolizumab are in the early
stages of use for patients with MSI-H mCRC and further studies are
needed to understand best practice for using these agents. The use
of re-challenge with anti-EGFR monoclonal antibodies has a bio-
logical rationale in the dynamic clonal competition of RAS-mutated
cancer cells that takes place during previous EGFR-targeted ther-
apy95; however, this approach should be conﬁrmed in prospective
trials that are ongoing. Furthermore, in patients with anti-EGFR
antibody-naive mCRC, recent results from the REVERCE
study,44 which assessed the sequencing of regorafenib and cetux-
imab plus irinotecan, are interesting and may challenge current
thinking on treatment sequencing, especially if this evaluation is
repeated in a Western population. In addition, combination trials of
regorafenib plus triﬂuridine/tipiracil (NCT03305913) and tri-
ﬂuridine/tipiracil plus bevacizumab (UMIN000012883, C-TASK
FORCE [TAS-102 plus bevacizumab in patients with mCRC re-
fractory to standard therapies])101 are underway, and these results
may also inform treatment sequencing.
Evaluation of immune checkpoint inhibitors in combination
with currently available therapies and with other checkpoint in-
hibitors, for example nivolumab plus ipilimumab,29 are ongoing, as
such combinations are associated with survival beneﬁts but can also
be associated with higher levels of toxicity compared with mono-
therapy.102 The results from such studies could inform treatment
Tanios Bekaii-Saab et alselection and sequencing decisions and would need to be incorpo-
rated into best-practice recommendations for patients with mCRC.
New molecularly targeted combination therapies are also being
investigated for third-line and later-line treatment, potentially of-
fering a different approach to treatment for some patients with
mCRC. The anti-HER2 antibody trastuzumab in combination with
the dual EGFR/HER2 kinase inhibitor lapatinib has shown promise
in the HERACLES (HER2 Ampliﬁcation for Colo-rectaL cancer
Enhanced Stratiﬁcation study; EudraCT number 2012-002128-33)
study, with an overall response rate of 30% in patients with RAS
WT, HER2/neu-overexpressing mCRC.103 Similarly, combination
therapy using trastuzumab and pertuzumab has shown efﬁcacy in
the MyPathway phase IIa multiple basket study, in which 37 pa-
tients with ERBB2-ampliﬁed/HER2 overexpressed mCRC who had
exhausted standard treatments were included and an overall
response rate of 38% was achieved.36 Ongoing studies are also
evaluating the potential of combining pertuzumab with trastuzu-
mab emtansine (T-DM1) in this patient population.103 The highly
selective HER2 tyrosine kinase inhibitor tucatinib is also being
assessed in combination with trastuzumab in patients with HER2-
positive CRC, as tumor inhibition has been observed in preclinical
models.104
Several other novel agents are being investigated as third-line or
later-line treatment options for mCRC.3 Tyrosine kinase
inhibitors, such as famitinib (NCT02390947), fruquintinib,105 and
anlotinib (NCT02332499), are under investigation in phase III
trials. The alkylating agent temozolomide showed some activity in
phase II studies of patients with mCRC and O6-methylguanine
DNA methyltransferase (MGMT) promoter methylation,106,107
even though molecular selection might be further improved
leaving the latter approach under investigation.108 The synergy
between BRAF and EGFR inhibition in patients with BRAF mu-
tations, as well as novel approaches such as the potential reversal of
EGFR-inhibitor resistance with heat shock protein 90 and stem cell
inhibitors, are also being assessed in ongoing research. Together,
this wealth of active clinical research highlights the continuing
efforts to improve quality of life and overall outcomes for patients
with mCRC.
In conclusion, third-line and later-line treatment of mCRC
requires a clear strategy to ensure patients receive maximum beneﬁt
while maintaining quality of life. Sharing current best practice
approaches, based on expert guidance from several regions, as well as
clinical and real-world evidence, can inform treatment decision-
making and ultimately improve the overall management of
patients with mCRC.Acknowledgments
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